Print this page Close this page

Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1446488

Sunesis Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

Description:
Sunesis Pharmaceuticals, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Sunesis Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Sunesis Pharmaceuticals, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Sunesis Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Sunesis Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Sunesis Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Sunesis Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Sunesis Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Sunesis Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Sunesis Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Sunesis Pharmaceuticals, Inc. and identify potential opportunities in those areas.
Contents:

List of Tables
List of Figures
Sunesis Pharmaceuticals, Inc. Snapshot
Sunesis Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Sunesis Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Sunesis Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Sunesis Pharmaceuticals, Inc. – Pipeline Products Glance
Sunesis Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Sunesis Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Sunesis Pharmaceuticals, Inc. – Drug Profiles
Vosaroxin
Product Description
Mechanism of Action
R&D Progress
Vosaroxin + Cytarabine
Product Description
Mechanism of Action
R&D Progress
SNS-032
Product Description
Mechanism of Action
R&D Progress
SNS-314
Product Description
Mechanism of Action
R&D Progress
Vosaroxin
Product Description
Mechanism of Action
R&D Progress
Sunesis/Merck BACE Target Program
Product Description
Mechanism of Action
R&D Progress
Sunesis Pharmaceuticals, Inc. – Pipeline Analysis
Sunesis Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Sunesis Pharmaceuticals, Inc. Pipeline Products By Target
Sunesis Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Sunesis Pharmaceuticals, Inc. – Recent Pipeline Updates
Sunesis Pharmaceuticals, Inc. - Dormant Projects
Sunesis Pharmaceuticals, Inc. – Company Statement
Sunesis Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Nov 15, 2010: Sunesis Receives US Patent Covering Vosaroxin Clinical Formulation
Nov 10, 2010: Sunesis Announces Positive Phase II Data For Vosaroxin In Acute Myeloid Leukemia
Aug 04, 2010: Sunesis Appoints Steering Committee And Clinical Partners For Vosaroxin Pivotal Phase III Trial In Acute Myeloid Leukemia
Jul 15, 2010: Sunesis Receives European Patent Covering Voreloxin Combination
Jun 07, 2010: Sunesis Reports Data From Phase II Clinical Program Of Voreloxin Combination Therapy In Acute Myeloid Leukemia
Jun 07, 2010: Sunesis Reports Data From Phase II Clinical Program Of Voreloxin In Acute Myeloid Leukemia And Ovarian Cancer
Jun 07, 2010: Sunesis Reports Data From Phase II Clinical Program Of Voreloxin In Acute Myeloid Leukemia And Ovarian Cancer
Jan 21, 2010: Sunesis Completes Enrollment Of Voreloxin Phase Ib/II Combination Trial In Acute Myeloid Leukemia
Jan 15, 2010: Sunesis Announces Publication Of Nonclinical Voreloxin Data In Leukemias
Nov 05, 2009: Sunesis' Voreloxin Receives FDA Orphan Drug Designation For Acute Myeloid Leukemia.
Financial Deals Landscape
Sunesis Pharmaceuticals, Inc., Deals Volume Summary, 2004 to YTD 2010
Sunesis Pharmaceuticals, Inc., Deals Summary By Region, 2004 to YTD 2010
Sunesis Pharmaceuticals, Inc., Deals Summary, 2004 to YTD 2010
Sunesis Pharmaceuticals, Inc. Detailed Deal Summary
Asset Purchase
Sunesis Pharmaceuticals Sells LFA-1 Inhibitor Program To SARcode
Equity Offering
Sunesis Pharmaceuticals Completes Private Placement Of $28.5 Million
Sunesis Pharmaceuticals Completes Private Placement Of $15 Million
Sunesis Pharmaceuticals Completes Second Tranche Of Private Placement For $5 Million
Sunesis Pharmaceuticals Completes Public Offering Of $21 Million
Sunesis Pharmaceuticals Completes Private Placement Of $45 Million
Sunesis Pharmaceuticals Completes Initial Public Offering Of $42 Million
Sunesis Pharmaceuticals Extends Research Collaboration With Johnson & Johnson
Sunesis Pharmaceuticals Enters Into An Agreement With Biogen Idec
Sunesis Pharmaceuticals Enters Into Research Collaboration With Merck
Sunesis Pharmaceuticals Extends Research Collaboration With J&JPRD
Sunesis Pharmaceuticals Terminates Research Collaboration Agreement With Johnson & Johnson Pharmaceutical
Sunesis Pharmaceuticals Terminates Research Agreement With Biogen Idec
Licensing Agreements
Sunesis Pharmaceuticals Enters Into Licensing Agreement With Carmot Therapeutics
CyDex Enters Into Licensing Agreement With Sunesis Pharmaceuticals
Sunesis Pharmaceuticals Enters Into Licensing Agreement With SARcode
Sunesis Pharmaceuticals Enters Into Research and License Agreement With University Of California
Sunesis Pharmaceuticals Enters Into Licensing Agreement With SARcode
Sunesis Pharmaceuticals Enters Into Licensing Agreement With Bristol-Myers Squibb
Sunesis Pharmaceuticals Enters Into Licensing Agreement With Biogen Idec
Sunesis Terminates Its Licesning Agreement With SARcode
Sunesis Pharmaceuticals Terminates Licensing Agreement With Bristol-Myers Squibb
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2
Printed Thursday, May 23, 2013
6:46:42 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Sunesis Pharmaceuticals, Inc. - Product Pipeline Review - Q4 2010

Web Address

http://www.researchandmarkets.com/reports/1446488

Office Code

OC8DIQSOLOWSYY

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User EURO€ 384.00
Electronic (PDF) - Site License EURO€ 769.00
Electronic (PDF) - Enterprisewide EURO€ 1,153.00

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Thursday, May 23, 2013
6:46:42 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)